| Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 386 (10001), 1341-1352, 2015 | 1275 | 2015 |
| Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial J Cuzick, I Sestak, M Baum, A Buzdar, A Howell, M Dowsett, JF Forbes The lancet oncology 11 (12), 1135-1141, 2010 | 1137 | 2010 |
| First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. J Cuzick, J Forbes, R Edwards, M Baum, S Cawthorn, A Coates, A Hamed, ... Lancet (London, England) 360 (9336), 817-824, 2002 | 888 | 2002 |
| Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy M Dowsett, I Sestak, E Lopez-Knowles, K Sidhu, AK Dunbier, JW Cowens, ... Journal of Clinical Oncology 31 (22), 2783-2790, 2013 | 734 | 2013 |
| Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial J Cuzick, JF Forbes, I Sestak, S Cawthorn, H Hamed, K Holli, A Howell Journal of the National Cancer Institute 99 (4), 272-282, 2007 | 642 | 2007 |
| Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial J Cuzick, I Sestak, JF Forbes, M Dowsett, J Knox, S Cawthorn, ... The Lancet 383 (9922), 1041-1048, 2014 | 632 | 2014 |
| Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial J Cuzick, I Sestak, SE Pinder, IO Ellis, S Forsyth, NJ Bundred, JF Forbes, ... The lancet oncology 12 (1), 21-29, 2011 | 618 | 2011 |
| Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data J Cuzick, I Sestak, B Bonanni, JP Costantino, S Cummings, A DeCensi, ... The Lancet 381 (9880), 1827-1834, 2013 | 565 | 2013 |
| Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial J Cuzick, I Sestak, S Cawthorn, H Hamed, K Holli, A Howell, JF Forbes The lancet oncology 16 (1), 67-75, 2015 | 512 | 2015 |
| Development and verification of the PAM50-based Prosigna breast cancer gene signature assay B Wallden, J Storhoff, T Nielsen, N Dowidar, C Schaper, S Ferree, S Liu, ... BMC medical genomics 8, 1-14, 2015 | 485 | 2015 |
| Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene … DC Sgroi, I Sestak, J Cuzick, Y Zhang, CA Schnabel, B Schroeder, ... The lancet oncology 14 (11), 1067-1076, 2013 | 437 | 2013 |
| Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial I Sestak, W Distler, JF Forbes, M Dowsett, A Howell, J Cuzick Journal of Clinical Oncology 28 (21), 3411-3415, 2010 | 356 | 2010 |
| Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial I Sestak, R Buus, J Cuzick, P Dubsky, R Kronenwett, C Denkert, S Ferree, ... JAMA oncology 4 (4), 545-553, 2018 | 305 | 2018 |
| CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients JM Rae, S Drury, DF Hayes, V Stearns, JN Thibert, BP Haynes, J Salter, ... Journal of the National Cancer Institute 104 (6), 452-460, 2012 | 303 | 2012 |
| Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and … I Sestak, J Cuzick, M Dowsett, E Lopez-Knowles, M Filipits, P Dubsky, ... Journal of clinical oncology, 2015 | 267 | 2015 |
| Factors predicting late recurrence for estrogen receptor–positive breast cancer I Sestak, M Dowsett, L Zabaglo, E Lopez-Knowles, S Ferree, JW Cowens, ... Journal of the National Cancer Institute 105 (19), 1504-1511, 2013 | 249 | 2013 |
| Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis I Sestak, J Cuzick, F Sapunar, R Eastell, JF Forbes, AR Bianco, ... The lancet oncology 9 (9), 866-872, 2008 | 237 | 2008 |
| Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy R Buus, I Sestak, R Kronenwett, C Denkert, P Dubsky, K Krappmann, ... Journal of the National Cancer Institute 108 (11), djw149, 2016 | 232 | 2016 |
| Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis SG Smith, I Sestak, A Forster, A Partridge, L Side, MS Wolf, R Horne, ... Annals of Oncology 27 (4), 575-590, 2016 | 232 | 2016 |
| Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial J Cuzick, I Sestak, D Cella, L Fallowfield The lancet oncology 9 (12), 1143-1148, 2008 | 229 | 2008 |
Jack CuzickQueen Mary Univeristy of LondonVerified email at qmul.ac.uk
